10:03 , Dec 7, 2017 |  BC Extra  |  Financial News

Metacrine raises $22M series B

Chronic disease company Metacrine Inc. (San Diego, Calif.) raised $22 million in a series B round led by new investor New Enterprise Associates. Existing investors Arch Venture Partners, Polaris, venBio and Alexandria Venture Investments also...
15:12 , Sep 1, 2017 |  BC Week In Review  |  Financial News

Longevity closes second fund at $22M

Longevity Fund (Palo Alto, Calif.) closed its second fund at $22 million. The firm's Laura Deming told BioCentury that it plans to invest in eight to 10 companies, with investments focused on companies with "the...
18:36 , Aug 23, 2017 |  BC Extra  |  Financial News

Longevity closes second fund at $22M

Longevity Fund closed its second fund at $22 million. The firm's Laura Deming told BioCentury that it plans to invest in eight to 10 companies, with investments focused on companies with "the potential to impact...
16:29 , Aug 18, 2017 |  BC Week In Review  |  Company News

Metacrine partners with Novo Nordisk to develop FGF1 variants

Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants for glucose lowering and insulin sensitization. Metacrine said it has developed a large library of FGF1...
22:03 , Aug 15, 2017 |  BC Extra  |  Company News

Metacrine, Novo Nordisk to develop FGF1 variants

Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants for glucose lowering and insulin sensitization. Metacrine said it has developed a large library of FGF1...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fibroblast growth factor 1 (FGF1)

Hepatic disease INDICATION: Liver disease Mouse studies suggest FGF1 could help treat non-alcoholic fatty liver disease (NAFLD). In a mouse model of NAFLD, mouse FGF1 decreased hepatic inflammation, hepatic steatosis and liver damage compared with vehicle. In...
07:00 , Aug 14, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Fibroblast growth factor 1 (FGF1) Mouse studies suggest recombinant FGF1 could help treat type 2...
07:00 , Apr 29, 2013 |  BioCentury  |  Strategy

Zerhouni's progress report

When Elias Zerhouni joined Sanofi as the head of R&D in January 2011, the former NIH director decided the pharma's pipeline needed to be pruned and refocused around disease pathways. Two years into the job,...
07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program (see "Repurposing pharma compounds"). The compounds provided...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

CVBT-141B: Phase IIa data

In a double-blind Phase IIa trial, CVBT-141B healed diabetic wounds about 4.5 times faster than placebo plus standard of care. No significant drug-related adverse events were observed. CardioVascular plans to apply for Fast Track Designation...